Project description
A platform for predicting neurotoxicity of drug candidates
Many drug candidates can introduce toxicity in the central nervous system, which can be poorly predicted during the research and development process. To address this problem, the EU-funded NeuroDeRisk project will study the mechanisms of neurotoxicity, specifically manifested as seizures, psychiatric changes and peripheral neuropathies. Researchers will develop a platform that integrates biological models, artificial intelligence, biomarkers, omics data and compound design tools to improve risk-assessment during the drug development pipeline. This platform will support decision-making in the pharmaceutical industry, offering better protection of human volunteers and patients.
Objective
The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicinetoxicology
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1010 Wien
Austria
See on map
Participants (17)
1090 Wien
See on map
11010 BELGRADE
See on map
2344 Maria Enzersdorf
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
70211 KUOPIO
See on map
50121 Florence
See on map
4051 401 Porto
See on map
751 05 Uppsala
See on map
13790 Peynier
See on map
63000 Clermont Ferrand
See on map
167 77 Athina
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
94250 GENTILLY
See on map
151 85 Sodertaelje
See on map
53711 Madison Wi
See on map
08889 Whitehouse Station Nj
See on map
4056 Basel
See on map
CT13 9NJ Sandwich
See on map
1070 Bruxelles / Brussel
See on map